62 search results for: asthma
EAACI 2025 | At The Intersection of the Type 2 Airways: Navigating the Challenges of CRSwNP & Co-existing Asthma
Professors Brian Lipworth, Zuzana Diamant, and Philippe Gevaert delve into the complexities of managing patients with both severe and/or uncontrolled CRSwNP and co-existing asthma through an evaluation of the diagnostic challenges, personalized treatment strategies, and the latest advancements in understanding the interconnected pathophysiology of these type 2 airway diseases.
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact
Join Professors Brusselle and Backer as they discuss the concept of disease modification in asthma.
Head-to-Head Trials of Biologics in CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
ADVENT at ERS 2026
Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.
How Can FeNO Measurement Improve Severe Asthma Management?
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Compounded Burden of Co-existing Type 2 Airway Diseases
In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
World Lung Day 2024
September 25th marks this year’s observance and celebration of World Lung Day!
Mechanisms of Production and Clinical Impact of IgE
Explore how type 2 inflammation drives the production of IgE in severe asthma
Exploring the Mechanisms of FeNO Production in the Lungs
Explore how type 2 inflammation drives the production of FeNO in severe asthma
Type 2 Asthma Learning Hub
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.
